Ryvu Therapeutics (WAR:RVU) FCF Margin % : -203.77% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ryvu Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was zł-44.03 Mil. Ryvu Therapeutics's Revenue for the three months ended in Mar. 2024 was zł21.61 Mil. Therefore, Ryvu Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -203.77%.

As of today, Ryvu Therapeutics's current FCF Yield % is -8.92%.

The historical rank and industry rank for Ryvu Therapeutics's FCF Margin % or its related term are showing as below:

WAR:RVU' s FCF Margin % Range Over the Past 10 Years
Min: -1089.94 Med: -69.02 Max: 30.89
Current: -185.79

During the past 13 years, the highest FCF Margin % of Ryvu Therapeutics was 30.89%. The lowest was -1089.94%. And the median was -69.02%.

WAR:RVU's FCF Margin % is ranked worse than
53.65% of 1040 companies
in the Biotechnology industry
Industry Median: -137.43 vs WAR:RVU: -185.79

Ryvu Therapeutics FCF Margin % Historical Data

The historical data trend for Ryvu Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics FCF Margin % Chart

Ryvu Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,089.94

-290.75

-684.19

30.89

-198.74

Ryvu Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-263.18	-241.10	-77.55	-214.38	-203.77

Competitive Comparison of Ryvu Therapeutics's FCF Margin %

For the Biotechnology subindustry, Ryvu Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ryvu Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's FCF Margin % falls into.

Ryvu Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ryvu Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-93.129	/	46.86
	=	-198.74 %

Ryvu Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-44.027	/	21.606
	=	-203.77 %

Ryvu Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ryvu Therapeutics (WAR:RVU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Leona Henryka Sternbacha 2, Krakow, POL, 30-394

Website

https://www.ryvu.com

Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics (WAR:RVU) Headlines

No Headlines